A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
DEMOGRAPHICS, PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS TREATED WITH PALBOCICLIB IN A REAL LIFE SETTING IN ISRAEL
Sponsor: Pfizer
This observational or N/A phase trial investigates Metastatic Breast Cancer and is currently completed. Pfizer leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Completed
-
Sep 2025 — Jan 2026 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Nov 2023 — Jul 2024 [monthly]
Completed
▶ Show 5 earlier versions
-
Sep 2023 — Nov 2023 [monthly]
Completed
-
Feb 2022 — Sep 2023 [monthly]
Completed
Status: Recruiting → Completed
-
Apr 2021 — Feb 2022 [monthly]
Recruiting
Status: Active Not Recruiting → Recruiting
-
Feb 2021 — Apr 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .